GlassScriptPhysician profile
Katarina S Harris
NPI 1003963141
$3,414.58
in general payments reported to CMS, 2019-2025
39 companies · $84.30 in 2025
The $84.30 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $662 · 2020: $486 · 2021: $476 · 2022: $1,102 · 2023: $488 · 2024: $115 · 2025: $84.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $687.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $552.72 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Electromed, INC. | $459.45 | 2021-2024 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $391.67 | 2020-2023 | Breztri, Fasenra, Symbicort |
| Philips North America LLC | $213.37 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $191.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.46 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $134.43 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $114.93 | 2022-2023 | Dupixent |
| Genzyme Corporation | $97.54 | 2019-2023 | |
| United Therapeutics Corporation | $95.01 | 2020-2022 | |
| Inspire Medical Systems, INC. | $93.15 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $81.28 | 2019-2021 | |
| Insmed, INC. | $80.50 | 2020-2022 | |
| Genentech USA, INC. | $73.21 | 2019-2023 | Esbriet, Xolair |
| Grifols USA, LLC | $70.84 | 2020-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $65.83 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.19 | 2020-2022 | |
| Gilead Sciences, INC. | $43.24 | 2019 | |
| Ambu INC. | $38.98 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.46 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $30.81 | 2023 | Quviviq |
| Astellas Pharma US INC | $30.05 | 2020-2024 | Xtandi |
| Merck Sharp & Dohme LLC | $29.50 | 2020 | |
| Hospira, INC. | $26.40 | 2022 | |
| Advanced Respiratory, INC | $24.05 | 2020-2021 | |
| Shire North American Group INC | $23.97 | 2019 | |
| Jazz Pharmaceuticals INC. | $20.55 | 2020 | |
| Vapotherm INC | $20.34 | 2022 | |
| La Jolla Pharmaceutical Company | $18.08 | 2021 | |
| Mallinckrodt Hospital Products INC. | $16.58 | 2021 | |
| Abbvie INC. | $16.20 | 2021 | |
| Amgen INC. | $15.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2019 | |
| Harmony Biosciences LLC | $13.05 | 2020 | |
| Ekos Corporation | $12.53 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.20 | 2019 | |
| Pulmonx Corporation | $12.17 | 2020 | |
| Janssen Pharmaceuticals, INC | $11.99 | 2021 | |
| Circassia INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katarina Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.